SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D.C. 20549

                                   FORM 10-Q

                  QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                      For the quarter ended March 31, 2010

                         Commission File Number 0-10683

                                 HYDROMER, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)

     New Jersey                                                22-2303576
----------------------                                -------------------------
(State of incorporation)                                  (I.R.S. Employer
                                                          Identification No.)

35 Industrial Pkwy, Branchburg, New Jersey                     08876-3424
------------------------------------------            -------------------------
  (Address of principal executive offices)                     (Zip Code)

Registrant's telephone number, including area code:        (908) 722-5000
                                                      -------------------------

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

                         Common Stock Without Par Value
                         ------------------------------
                                (Title of class)

   Indicate  by  check  mark  whether  the  registrant (1) has filed all reports
required  to  be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant was required to file such report(s), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X]       No [ ]

   Indicate  by  check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer [ ]             Accelerated filer               [ ]
Non-accelerated filer   [ ]             Smaller reporting company       [X]

   Indicate  by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).

Yes [ ]         No [X]



         Class                                  Outstanding at March 31, 2010
         -----                                  -----------------------------
        Common                                             4,772,318




















<PAGE>
                           FORWARD-LOOKING STATEMENTS

This  quarterly  report  on Form 10-Q contains forward-looking statements within
the  meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements include, among other
things,  business  strategy  and  expectations  concerning  industry conditions,
market  position,  future  operations,  margins,  profitability,  liquidity  and
capital resources. Forward-looking statements generally can be identified by the
use  of  terminology  such  as  "may,"  "will,"  "expect," "intend," "estimate,"
"anticipate" or "believe" or similar expressions or the negatives thereof. These
expectations  are based on management's assumptions and current beliefs based on
currently   available  information.  Although  the  Company  believes  that  the
expectations  reflected  in  such  statements  are  reasonable,  it  can give no
assurance that such expectations will be correct. You are cautioned not to place
undue  reliance  on these forward-looking statements, which speak only as of the
date  of  this  quarterly  report on Form 10-Q and the Company does not have any
obligation  to  update  the forward looking statements. The Company's operations
are  subject  to  a number of uncertainties, risks and other influences, many of
which  are outside its control, and any one of which, or a combination of which,
could  cause  its  actual  results  of  operations to differ materially from the
forward-looking statements.
























































                                       1
<PAGE>
                                 HYDROMER, INC.


                               INDEX TO FORM 10-Q
                                 March 31, 2010

<TABLE>
<S>                                          <C>                                                <C>
                                                                                             Page No.
Part I  -  Financial Information

      # 1  Consolidated Financial Statements

             Balance Sheets - March 31, 2010 & June 30, 2009                                    3

             Statements of Operations for the three months and nine months ended                4
                 March 31, 2010 and 2009

             Statements of Cash Flows for the nine months ended
                 March 31, 2010 and 2009                                                        5

             Notes to Financial Statements                                                      6

      # 2  Management's Discussion and Analysis of the Financial Condition
                 and Results of Operations                                                      8

      # 3  Controls and Procedures                                                             10


Part II  -  Other Information

      # 1  Legal Proceedings                                                                  N/A

      # 2  Change in Securities                                                               N/A

      # 3  Default of  Senior Securities                                                      N/A

      # 4  Submission of Motion to Vote of Security Holders                                   N/A

      # 5  Other Information                                                                  N/A

      # 6  Exhibits                                                                            10


                                        EXHIBIT INDEX

Exhibit No.      Description of Exhibit
-----------      ----------------------
31.1             SEC Section 302 Certification - CEO certification                             13
31.2             SEC Section 302 Certification - CFO certification                             14

32.1             Certification of Manfred F. Dyck, Chief Executive Officer,
                         pursuant to 18 U.S.C. Section 1350                                    15

32.2             Certification of Robert Y. Lee, Chief Financial Officer,
                         pursuant to 18 U.S.C. Section 1350                                    15

</TABLE>



















                                       2
<PAGE>
PART I - CONSOLIDATED FINANCIAL STATEMENTS
ITEM # 1

                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS

<TABLE>
<S>                                                                              <C>                <C>
                                                                                 March 31,          June 30,
                                                                                   2010               2009
                                                                                 UNAUDITED          AUDITED
      ASSETS
      Current Assets:
          Cash and cash equivalents                                          $     1,186,790   $     1,585,765
          Short-term investments                                                     440,000           450,000
          Trade receivables less allowance for doubtful accounts of $40,120
            and $57,741 as of March 31, 2010 and June 30, 2009, respectively         871,724         1,058,978
          Inventory                                                                  244,059           615,849
          Prepaid expenses                                                           194,667           204,280
          Deferred tax asset                                                           8,976             8,976
          Other                                                                       27,011             8,968
      ----------------------------------------------------------------------------------------------------------
      Total Current Assets                                                         2,973,227         3,932,816
      ----------------------------------------------------------------------------------------------------------

      Property and equipment, net                                                  2,978,863         3,135,017
      Deferred tax asset, non-current                                              1,001,512           521,986
      Intangible assets, net                                                         841,913           740,426
      ----------------------------------------------------------------------------------------------------------
      Total Assets                                                           $     7,795,515   $     8,330,245
      ----------------------------------------------------------------------------------------------------------

      LIABILITIES AND STOCKHOLDERS' EQUITY
      Current Liabilities:
          Accounts payable                                                   $       439,102   $       380,838
          Accrued expenses                                                           349,942           341,088
          Current portion of capital lease                                            15,603            14,473
          Current portion of deferred revenue                                         71,331            82,132
          Current portion of mortgage payable                                         47,976            45,696
          Income tax payable                                                           1,040            75,891
      ----------------------------------------------------------------------------------------------------------
      Total Current Liabilities                                                      924,994           940,118
      ----------------------------------------------------------------------------------------------------------
      Deferred tax liability                                                         343,967           285,858
      Long-term portion of capital lease                                              38,867            50,258
      Long-term portion of deferred revenue                                          188,934           161,019
      Long-term portion of mortgage payable                                        2,781,757         2,820,055
      ----------------------------------------------------------------------------------------------------------
      Total Liabilities                                                            4,278,519         4,257,308
      ----------------------------------------------------------------------------------------------------------

      Stockholders' Equity
          Preferred stock - no par value, authorized 1,000,000 shares, no
             shares issued and outstanding                                               -                 -
          Common stock - no par value, authorized 15,000,000 shares;
               4,783,235 shares issued and 4,772,318 shares outstanding as
               of March 31, 2010 and June 30, 2009                                 3,721,815         3,721,815
          Contributed capital                                                        633,150           633,150
          Accumulated deficit                                                       (831,829)         (275,888)
          Treasury stock, 10,917 common shares at cost                                (6,140)           (6,140)
      ----------------------------------------------------------------------------------------------------------
      Total Stockholders' Equity                                                   3,516,996         4,072,937
      ----------------------------------------------------------------------------------------------------------
      Total Liabilities and Stockholders' Equity                             $     7,795,515   $     8,330,245
      ----------------------------------------------------------------------------------------------------------
</TABLE>

                                                    See accompanying notes









                                       3
<PAGE>
                              HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                                CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<S>                                                      <C>              <C>             <C>              <C>

                                                               Three Months Ended                Nine months Ended
                                                                    March 31,                        March 31,
                                                               2010            2009               2010            2009
                                                            UNAUDITED        UNAUDITED          UNAUDITED       UNAUDITED
---------------------------------------------------------  -----------------------------    ------------------------------
REVENUES
    Sale of products                                     $     845,734    $  1,012,814    $     2,856,840  $    3,366,415
    Service revenues                                           402,766         635,947          1,062,049       1,648,023
    Royalties and Contract Revenues                            226,668         183,946            681,964       1,003,939
                                                         --------------   ------------    ---------------  --------------
         TOTAL REVENUES                                      1,475,168       1,832,707          4,600,853       6,018,377
-------------------------------------------------------- -----------------------------    -------------------------------

EXPENSES

   Cost of Sales                                               526,601        851,318           1,994,058       2,497,874
   Operating Expenses                                        1,316,952      1,295,123           3,804,805       3,639,671
   Other Expenses                                               56,973        151,811             138,611         239,378
   Gain from Sale of Assets                                          -     (1,293,348)           (335,629)     (1,293,348)
   (Benefit from) Provision for Income Taxes                  (218,942)       308,000            (445,051)        336,000
                                                         --------------   ------------    ---------------  --------------

         TOTAL EXPENSES                                      1,681,584      1,312,904           5,516,794       5,419,575
-------------------------------------------------------- -----------------------------    -------------------------------

         NET (LOSS) INCOME                               $    (206,416)   $   519,803     $      (555,941)  $     598,802
-------------------------------------------------------- -----------------------------    -------------------------------

         (Loss) Earnings Per Common Share                $       (0.04)   $      0.11     $         (0.12)  $        0.13

Weighted Average Number of
         Common Shares Outstanding                           4,772,318      4,772,318           4,772,318       4,772,318
         Common Shares Outstanding assuming dilution                        4,773,655                           4,772,986


                                       See accompanying notes.

                There  was  no  impact  to  earnings  per  share  from  dilutive
securities. For the 2010 period, the resultant would have been anti-dilutive.
</TABLE>
































                                       4
<PAGE>
                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
                     CONSOLIDATED STATEMENTS OF CASH FLOWS

<TABLE>
<S>                                                                                  <C>                    <C>
                                                                                       Nine months Ended
                                                                                           March 31,
                                                                                     2010            2009
                                                                                   UNAUDITED      UNAUDITED
         -----------------------------------------------------------------------------------------------------
         CASH FLOWS FROM OPERATING ACTIVITIES:
             Net (Loss) Income                                                 $    (555,941)  $     598,802
             Adjustments to reconcile net (loss) income to net cash

             (used for) provided by operating activities
                Gain on Sale of Product Lines                                       (335,629)     (1,293,348)
                Depreciation and amortization                                        318,126         313,725
                Charge-off of Patent Costs                                              -             63,242
                Reserve for Inventories                                                 -            100,000
                Valuation Allowance on Fixed Assets/Loss on Disposal of                 -            121,134
                Fixed Assets
                Deferred income taxes                                               (421,417)        337,652
                Changes in Assets and Liabilities:
                  Trade receivables                                                  187,254         144,516
                  Inventory                                                           75,296          74,905
                  Prepaid expenses                                                     9,611         (72,616)
                  Other assets                                                       (18,402)         (2,868)
                  Accounts payable and accrued liabilities                            67,118        (172,690)
                  Deferred income                                                     17,114         (35,391)
                  Income taxes payable                                               (89,212)         (4,772)
         -----------------------------------------------------------------------------------------------------

                      Net Cash (Used for) Provided by Operating Activities          (746,082)        172,291

         -----------------------------------------------------------------------------------------------------

         CASH FLOWS FROM INVESTING ACTIVITIES:
             Cash purchases of property and equipment                               (175,486)       (139,744)
             Cash payments on patents and trademarks                                (251,389)       (241,314)
             Redemption of matured short-term investments                            700,000            -
             Cash purchases of short-term investments                               (690,000)       (450,000)
             Proceeds Received from the sale of Product Lines                        800,000       1,066,667
         -----------------------------------------------------------------------------------------------------

                      Net Cash Provided by Investing Activities                      383,125         235,609

         -----------------------------------------------------------------------------------------------------
         CASH FLOWS FROM FINANCING ACTIVITIES:
             Net repayments toward Line of Credit                                       -           (289,973)
             Proceeds from long-term borrowings                                         -          2,900,000
             Repayment of long-term borrowings                                       (36,018)     (1,901,202)
         -----------------------------------------------------------------------------------------------------

                      Net Cash (Used for) Provided by Financing Activities           (36,018)        708,825

         -----------------------------------------------------------------------------------------------------
         NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS:                      (398,975)      1,116,725
         Cash and Cash Equivalents at Beginning of Period                          1,585,765         108,403
         -----------------------------------------------------------------------------------------------------

         Cash and Cash Equivalents at End of Period                            $   1,186,790   $   1,225,128
         -----------------------------------------------------------------------------------------------------


                            See accompanying notes.
</TABLE>











                                       5
<PAGE>
                   HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY

                   Notes to Consolidated Financial Statements

In  the  opinion  of management, the accompanying unaudited financial statements
include  all adjustments (consisting of only normal adjustments) necessary for a
fair   presentation   of   the   results   for   the  interim  periods.  Certain
reclassifications  have  been  made  to  the  previous year's results to present
comparable financial statements.


Significant Events:

On  November  25, 2009, the Company's wholly owned subsidiary, Biosearch Medical
Products,  Inc.  ("BMPI")  sold  its  Private  Label  Jejunostomy  Catheter  and
Nasogastric   Feeding   Catheter  business  to  Forefront  Medical  Technologies
("Forefront"),  a  wholly  owned subsidiary of Vicplas International Limited - a
company  registered  in  the  Republic  of Singapore, for $800,000 in cash, half
received  upon closing in November 2009 with the balance received in March 2010.
This  sale  included  inventory  and equipment related to that business and also
calls  for the assignment of certain customer supply agreements to Forefront and
a  three year non-compete provision. A separate supply agreement for Hydromer(R)
hydrophilic coating solution used on those products was also entered between the
parties.  BMPI  continued manufacturing the products, at an agreed upon transfer
price, until Forefront completed the transition in April 2010. Accordingly, this
transaction  does  not meet the criteria of Discontinued Operations of Financial
Accounting Standards Board ("FASB") Accounting Standards Codification paragraphs
205-20.  These  product  lines  sold were part of the "Medical Products" segment
(see following Segment Reporting section).

Recent Accounting Pronouncements
--------------------------------

In  February  2010, the FASB issued Update No. 2010-08 "Technical Corrections to
Various  Topics"  (ASU 2010-08). ASU 2010-08 represents technical corrections to
Securities  and  Exchange  Commission  (the  "SEC")  paragraphs  within  various
sections  of  the Codification. Management is currently evaluating whether these
changes  will  have  any  material  impact on its financial position, results of
operations or cash flows.

In  February  2010, the FASB issued Update No. 2010-09 "Subsequent Events (Topic
855)"  (ASU  2010-09).  ASU  2010-09  clarifies  the  interaction  of Accounting
Standards  Codification  855  "Subsequent  Events"  ("Topic  855") with guidance
issued  by  the SEC as well as the intended breadth of the reissuance disclosure
provision  related  to subsequent events found in paragraph 855-10-50-4 in Topic
855.  This  update  is effective for annual or interim periods ending after June
15, 2010. Management is currently evaluating whether these changes will have any
material impact on its financial position, results of operations or cash flows.

In  April  2010,  the  FASB issued ASU 2010-17, "Revenue Recognition - Milestone
Method  (Topic  605)" (ASU 2010-17). ASU 2010-17 provides guidance on defining a
milestone  and  determining  when  it  may be appropriate to apply the milestone
method  of  revenue  recognition  for research and development transactions. The
Update  provides  guidance  on  the  criteria that should be met for determining
whether  the milestone method of revenue recognition is appropriate. This update
is  effective  for  annual  or  interim  periods  ending  after  June  15, 2010.
Management  is currently evaluating whether these changes will have any material
impact on its financial position, results of operations or cash flows.


FAIR VALUE
----------

In  accordance with FASB ASC 820, "Fair Value Measurements and Disclosures", the
following  table represents the Company's fair value hierarchy for its financial
assets  and  liabilities measured at fair value on a recurring basis as of March
31, 2010:










                                       6
<PAGE>
        ---------------- ------------ ----------- ----------- ------------
                           Level 1     Level 2     Level 3       Total
                           -------     -------     -------       -----
        ASSETS
            Investments  $  440,000                           $  440,000
                            -------                              -------
        Total Assets     $  440,000       -           -       $  440,000
                            =======                              =======

        LIABILITIES - n/a      -          -           -            -
        ---------------- ------------ ----------- ----------- ------------

Some  of the Company's financial instruments are not measured at fair value on a
recurring  basis  but are recorded at amounts that approximate fair value due to
their   liquid  or  short-term  nature,  such  as  cash  and  cash  equivalents,
receivables  and  payables. The carrying amount of the Company's note obligation
approximates  its  fair value, as the terms of the note is consistent with terms
available in the market for instruments with similar risk.

Segment Reporting:
------------------
The  Company  operates  two primary business segments. The Company evaluates the
segments  by  revenues,  total  expenses  and  earnings  before taxes. Corporate
Overhead  is  excluded  from  the  business  segments  as  to  not  distort  the
contribution  of  each  segment.  These segments are the lowest levels for which
identifiable  cash  flows  are  largely  independent  of the cash flows of other
assets and liabilities.

The results for the nine months ended March 31, by segment are:

<TABLE>
<S>                                                     <C>           <C>               <C>           <C>
                                                      Polymer          Medical         Corporate
         Excludes the sale of product lines          Research          Products        Overhead          Total
         2010
         Revenues                                  $    2,936,347   $    1,664,506                  $   4,600,853
         Expenses                                      (3,000,632)      (1,746,469)  $ (1,190,373)     (5,937,474)
                                                  ----------------  ---------------   ------------   -------------
              Pre-tax Loss                         $      (64,285)  $      (81,963)  $ (1,190,373)  $  (1,336,621)
                                                  ================  ===============  =============   =============

         ---------------------------------------- ---------------- ----------------- -------------- ----------------
         2009
         Revenues                                  $   3,404,319    $    2,614,058                  $   6,018,377
         Expenses                                     (2,602,007)       (2,485,763)  $ (1,289,153)     (6,376,923)
                                                  ----------------  ---------------   ------------   -------------
              Pre-tax Income (Loss)               $      802,312    $      128,295  $  (1,289,153)   $   (358,546)
                                                  ================  ===============  =============   =============

</TABLE>


Geographic revenues were as follows for the nine months ended March 31,

                                                             2010      2009
                                                             ----      ----
                                 Domestic                     72%       83%
                                 Foreign                      28%       17%



















                                   7
<PAGE>
ITEM #2

                  MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                 ---------------------------------------------

Results of Operations
---------------------

The  Company's  revenues  for  the quarter ended March 31, 2010 were $1,475,168,
19.5%  lower  than the $1,832,707 for the same period the previous year. For the
nine  month  period  ended  March 31, 2010, revenues were $4,600,853 as compared
with  $6,018,377 the corresponding period a year ago; $1,417,524 or 23.6% lower.
Revenues  are  comprised  of  the  sale of Products and Services and Royalty and
Contract payments.

       Product  sales  were  $845,734  for  the  quarter ended March 31, 2010 as
       compared  to  $1,012,814  for the same period the year before, a $167,080
       (16.5%) decrease; lower due to the impact from the sales of product lines
       to  Merit  Medical  Systems,  Inc.  ("Merit")  in  February  2009  and to
       Forefront  Medical  Technologies  ("Forefront") in November 2009. For the
       nine  month  period, product sales were $2,856,840 for the current fiscal
       year  period  as  compared with $3,366,415 or $509,575 (15.1%) lower than
       the same period the year before.

       Services  revenues for the three months ended March 31, 2010 was $402,766
       or  $233,181 lower (36.7%) than the $635,947 the corresponding period the
       year  before.  Services revenues for the nine months ended March 31, 2010
       were  $1,062,049  or  $585,974 (35.6%) lower than the $1,648,023 the year
       before.  Included  in  the  prior  year's  revenues  was  $192,000 in R&D
       services  in  which  the  project  was completed during that prior fiscal
       year.  In  addition  the  conversion of a customer from contract coatings
       servicing  to  product  sales  accounted  for  $419,165 of lower services
       revenues during the current nine month period.

       Royalty and Contract revenues include royalties received and the periodic
       recurring  payments  from  license,  stand still and other agreements for
       other  than  product  and  services.  Included  in  Royalty  and Contract
       revenues  are  revenues  from  support and supply agreements. Some of the
       royalties  and  support fees are based on the net sales of the final item
       (to  which  the Hydromer technology is applied to) and are subject to the
       reporting of our customers. For the quarter ended March 31, 2010, Royalty
       and Contract revenues were $226,668, compared to $183,946 the same period
       a year ago. For the nine month period, Royalty and Contract revenues were
       $681,964   compared   to  $1,003,939  for  the  2010  and  2009  periods,
       respectively.  The  cancellation  of  a  supply  and support agreement of
       $100,000  per  month  effective  January  1,  2009, replaced by a similar
       agreement  at  $35,000  per  month,  was  the  primary  factor behind the
       difference.

       As  of  March  31,  2010,  our  open  sales  order book was approximately
       $412,000.  Although  some  of  the sales orders can be cancelled prior to
       production,   the   Company   is  of  the  opinion  that  no  substantial
       cancellations  will  occur.  This  value  is lower than previous reported
       periods  due  to the sale of product lines to Merit and Forefront and the
       conclusion  of the production transfer period. In addition, a majority of
       the  Company's  sales orders calls for immediate delivery (subject to the
       Company's  lead  time)  and thus distorts the periodically reported sales
       orders that the Company turns over.

Total  Expenses for the quarter ended March 31, 2010 were $1,681,584 as compared
with  $1,312,904  the  year  before, a 28.1% increase. For the nine months ended
March  31,  2010, total expenses were $5,156,794 as compared with $5,419,575 the
same  period the year before, lower by 4.8%. Reducing expenses was the gain from
the  sale of product lines of $335,629 for fiscal period 2010 and $1,293,348 for
fiscal period 2009

       For  the  quarter  ended March 31, 2010, the Company's Cost of Goods Sold
       was $526,601 as compared with $851,318 the year prior, lower by 38.1%. On
       a  year-to-date  basis,  Cost  of Goods Sold for fiscal 2009 (nine months
       ended  March  31,  2010)  was  $1,994,058  as compared with $2,497,874 in
       fiscal  2009,  or  $503,816 (20.2% lower). Lower product sales, including
       that  from  the  sale  of  product  lines  to  Merit  and Forefront which
       concluded  the  Company's  related  operations for those product lines in
       October  2009  and  April  2010 respectively, resulted in a lower Cost of
       Goods  Sold.

                                       8
<PAGE>


       Operating  expenses  were $1,316,952 for the quarter ended March 31, 2010
       as  compared with $1,295,123 the year before, up $21,829 or 1.7%. For the
       nine  months ended March 31, 2010, Operating Expenses were $3,804,805, up
       $165,134 or 4.5% from the $3,639,671 for the same period the year before.
       The  increased  international focus in our T-HEXX Animal Health business,
       including  a  dedicated  product  manager,  added  tradeshow  promotions,
       related  travel  and  marketing  expenses  resulted  in  higher  costs of
       $139,639  in  the  current  nine month period partially offset by patents
       write  offs  of $63,242 during the corresponding period. In addition, one
       time  legal  fees  of $47,840 relating to the freedom to market clearance
       review  was incurred during the nine month period. Such legal fees allows
       for a new Hydrogel product launch with legal clearance. In addition, this
       year  to  date  includes  $34,206 spent on animal clinical studies on our
       recently   launched  DragonhydeTM  Hoof  Bath  Concentrate.  All  of  the
       incremental  spends  this  period are directly in relation towards future
       revenue sources.

      Interest  expense,  interest income and other income are included in Other
      Expenses.  Interest  expense  for the nine months ended March 31, 2010 and
      March 31, 2009 were $152,817 and $150,383, respectively.

A net loss of $206,416 ($0.04 per share) is reported for the quarter ended March
31,  2010  as  compared  to  net  income  of $519,803 ($0.11 per share) the year
before.  For the nine months ended March 31, 2010, a net loss of $555,941 ($0.12
per share) compared against net income of $598,802 ($0.13 per share) for the
same period year before.

      The  cancellation  and  subsequent  entering  of a lower valued supply and
      support  agreement  impacted operating income by $390,000 as compared with
      the  prior  year.  The sale of product lines to Merit and Forefront had an
      approximate  $192,000  impact  to the revenue change between the years and
      the  subsequent transfer price agreement further impacted operating income
      by  another  $347,000.  An income tax benefit of $445,051 was recorded for
      the nine month period.

      Re-investment  expenditures  of  Research  and Development and patents and
      trademarks  expenditures  accounted for approximately $808,873 or 21.2% of
      the operating expenses.

Financial Condition
-------------------

Working capital decreased $944,465 during the nine months ended March 31, 2010.

Net  operating activities used $746,082 during the nine month period ended March
31, 2010.

      The net loss, as adjusted for non-cash expenses and less the gain from the
      sale  of  product  lines,  used  $994,861 in cash. The net change in other
      operating  assets  and  liabilities  provided for $248,779 in cash. Income
      taxes paid during the year were $134,851.

Investing  activities  provided  $383,125  and financing activities used $36,018
during the nine months ended March 31, 2010.

       Investing  activities  for  the nine months ended March 31, 2010 included
       $175,486  for  capital  expenditures  and  $251,389 towards the Company's
       patent  estate.  $700,000  in  short-term  investments  matured  of which
       $690,000  was  reinvested/renewed. Cash of $800,000 was received from the
       sale  of product lines. Under financing activities, the principal portion
       of debt servicing of the mortgage utilized $36,018 in cash.

Until replacement income is achieved, the cancellation of the $100,000 per month
Supply  and  Support  Agreement  and  the  sale  of  product  lines to Merit and
Forefront,  with  the  sales proceeds representing the future cash flows, pushes
the  Company  into an operating loss position for the near future. The timing of
new revenues, including that from its anti-microbial, anti-thrombogenic and cell
mitosis  technologies  and  new  T-HEXX  product lines and broaden T-HEXX market
penetration,  are in varying stages. The Company has a strong balance sheet
to meet its required debt servicing.





                                      9
<PAGE>
ITEM # 3

Disclosure Controls and Procedures
----------------------------------

   As  of  the  period  covered  by  this  report,  the  Company  carried out an
evaluation,  under the supervision and with the participation of our management,
including  the  Chief  Executive  Officer  and President and the Chief Financial
Officer,  of  the  effectiveness  of  the design and operation of the disclosure
controls and procedures.

    Based  upon this evaluation, our Chief Executive Officer and Chief Financial
Officer  concluded  that,  our disclosure controls and procedures were effective
and  that there were no changes to our Company's internal control over financial
reporting  that  have materially affected, or is reasonably likely to materially
affect the Company's internal control over financial reporting during the period
covered by the Company's quarterly report.

PART II - OTHER INFORMATION

   The Company operates entirely from its sole location at 35 Industrial Parkway
in  Branchburg,  New  Jersey,  an owned facility secured by a mortgage through a
bank.

   The  existing  facility will be adequate for the Company's operations for the
foreseeable future.

ITEM # 6. Exhibits

      Exhibit No.    Description
      ------------   ------------
          31.1       Rule 13a-14(a) Certification of Chief Executive Officer and
                        President
          31.2       Rule  13a-14(a) Certification of Vice President of  Finance
                        and Chief Financial  Officer
          32.1       Section 1350  Certification  of Chief Executive Officer and
                        Chairman, President
          32.2       Section 1350 Certification of Chief Financial  Officer  and
                        Vice President of Finance






































                                       10
<PAGE>


                                   SIGNATURES
                                   ----------

Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on his behalf by the
undersigned thereunto duly authorized.

                                            HYDROMER, INC.


                                            /s/Robert Y. Lee,VP
                                            -------------------
                                            Robert Y. Lee
                                            Principal Accounting Officer & Chief
                                                Financial Officer



DATE: May 17, 2010
























































                                       11
<PAGE>
                                  EXHIBIT 31.1
                                 -------------

I, Manfred F. Dyck, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's  other  certifying officer, Mr. Robert Y. Lee and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        disclosed,  based  on  our  most  recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's other certifying officer, Mr. Robert Y. Lee and I have
        indicated  in  this  quarterly  report  whether  there  were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: May 17, 2010

/s/Manfred F. Dyck
------------------------------------------
Manfred F. Dyck, President and CEO
<PAGE>
                                  EXHIBIT 31.2
                                 -------------

I, Robert Y. Lee, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydromer, Inc.;

2.      Based on my knowledge, this quarterly report does not contain any untrue
        statement  of a material fact or omit to state a material fact necessary
        to  make  the statements made, in light of the circumstances under which
        such  statements  were  made,  not misleading with respect to the period
        covered by this quarterly report;

3.      Based  on  my  knowledge,  the financial statements, and other financial
        information  included  in  this  quarterly report, fairly present in all
        material  respects  the  financial  condition, results of operations and
        cash  flows  of  the registrant as of, and for, the periods presented in
        this quarterly report;

4.      The  registrant's other certifying officer, Mr. Manfred F. Dyck and I am
        responsible  for  establishing  and  maintaining disclosure controls and
        procedures  (as  defined  in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and  internal  control  over financial reporting (as defined in Exchange
        Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

      a) designed  such  disclosure  controls  and  procedures,  or  caused such
         disclosure   controls   and   procedures   to  be  designed  under  our
         supervision,  to  ensure  that  material  information  relating  to the
         registrant,  including  its consolidated subsidiaries, is made known to
         us  by  others within those entities, particularly during the period in
         which this quarterly report is being prepared;

      b) designed  such  internal  controls  over financial reporting, or caused
         such  internal  controls  over financial reporting to be designed under
         our   supervision,  to  provide  reasonable  assurances  regarding  the
         reliability  of  financial  reporting  and the preparation of financial
         statements  for external purposes in accordance with generally accepted
         accounting principles

      c) evaluated the effectiveness of the registrant's disclosure controls and
         procedures  and  presented  in  this  report  our conclusions about the
         effectiveness  of the disclosure controls and procedures, as of the end
         of the period covered by this report based on such evaluation; and

      d) disclosed  in  this  report  any  change  in  the registrant's internal
         control  over financial reporting that occurred during the registrant's
         most  recent  fiscal quarter (the registrant's fourth fiscal quarter in
         case  of  an  annual  report)  that  has  materially  affected,  or  is
         reasonably  likely  to  materially  affect,  the  registrant's internal
         control over financial reporting;

5.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have disclosed, based on our most recent evaluation, to the registrant's
        auditors  and the audit committee of registrant's board of directors (or
        persons performing the equivalent functions):

      a) all  significant  deficiencies  in  the design or operation of internal
         controls  which  could  adversely  affect  the  registrant's ability to
         record,   process,   summarize  and  report  financial  data  and  have
         identified  for  the  registrant's  auditors any material weaknesses in
         internal controls; and

      b) any  fraud,  whether or not material, that involves management or other
         employees  who  have  a  significant  role in the registrant's internal
         controls; and

6.      The  registrant's  other  certifying  officer, Mr. Manfred F. Dyck and I
        have  indicated  in this quarterly report whether there were significant
        changes   in   internal   controls   or  in  other  factors  that  could
        significantly  affect  internal  controls  subsequent to the date of our
        most  recent evaluation, including any corrective actions with regard to
        significant deficiencies and material weaknesses.

Date: May 17, 2010

/s/Robert Y. Lee,VP
------------------------------------------
Robert Y. Lee, Vice President of Finance and CFO
<PAGE>
                                  EXHIBIT 32.1
                                  ------------

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Manfred  F.  Dyck,  certify,  pursuant to 18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report  of  Hydromer, Inc. on Form 10-Q for the nine months ended March 31, 2010
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: May 17, 2010                       By: /s/Manfred F. Dyck
                                            -----------------------
                                                Manfred F. Dyck
                                                Chairman, President and
                                                Chief Executive Officer


--------------------------------------------------------------------------------


                                  EXHIBIT 32.2
                                  ------------

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                  PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Robert  Y.  Lee,  certify,  pursuant  to  18 U.S.C. Section 1350, as adopted
pursuant  to  Section  906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report  of  Hydromer, Inc. on Form 10-Q for the nine months ended March 31, 2010
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange  Act  of  1934  and  that  information  contained in such report fairly
presents  in  all  material  respects  the  financial  condition  and results of
operations of Hydromer, Inc.

Date: May 17, 2010                       By: /s/Robert Y. Lee,VP
                                            -----------------------
                                                Robert Y. Lee
                                                Chief Financial Officer and Vice
                                                President of Finance